Advances in clinical research on efficacy of palonosetron in treatment of chemotherapy-induced nausea and vomiting

Palonosetron is the first 5-HT3 receptor antagonist approved for prevention of delayed chemotherapy-induced nausea and vomiting(CINV).Furthermore,palonosetron is at least as effective as first-generation 5-HT3 receptor antagonists in treatment of acute CINV,and is more effective than first-generation 5-HT3 receptor antagonists in treatment of delayed CINV.The progress of clinical study of palonosetron is reviewed in this article,and the safety and efficacy of multi-dose of palonosetron in treatment of CINV are also discussed.